Enfortumab

What it is used for

PADCEV ®, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).

PADCEV ®, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC).

PADCEV, as a single agent, is indicated for the treatment of adult patients with la/mUC who:

• have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or
• are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

Side effects, and when to stop

The following serious adverse reactions are described elsewhere in the labeling:

• Skin Reactions
• Hyperglycemia
• Pneumonitis/Interstitial Lung Disease (ILD)
• Peripheral Neuropathy
• Ocular Disorders
• Infusion Site Extravasation

Who should not take it

None.